You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥(01093.HK)蔡東晨:帶量採購牽動市場競爭變革 藥企唯有創新圖存
阿思達克 10-30 16:16

據《中國經營報》近日報道,石藥集團(01093.HK)董事局主席蔡東晨認為,今年9月以來在國家醫保局等部門指導下,參與藥品帶量採購擴圍的25個省份和新疆生產建設兵團在上海開展聯合招採,產生了擬中選結果。按照規則,聯盟採購的25個品種,將由入選的3家企業瓜分全國70%的市場。石藥集團出產的75mg規格的氯(口比)格雷藥品入選。

蔡東晨表示,帶量採購牽動的醫藥市場競爭規則的變革中,仿製藥生產企業面臨行業整合機遇。製藥企業要生存,就要創新、研發,在創新中求生存。

他指,近年來,國家在醫藥、醫保、醫療三個維度,供給側和需求側兩個方向進行了深度改革,醫藥產業趨勢發生變化。醫藥市場的競爭規則和競爭格局逐漸變化,輔助用藥、仿製藥整體份額面臨壓縮,創新藥整體份額逐步提升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account